UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.

OBJECTIVES: In 2002, the UK's National Institute for Health and Care Excellence concluded that the multiple sclerosis (MS) disease modifying therapies; interferon-β and glatiramer acetate, were not cost effective over the short term but recognised that reducing disability over the longer term m...

詳細記述

書誌詳細
主要な著者: Palace, J, Bregenzer, T, Tremlett, H, Oger, J, Zhu, F, Boggild, M, Duddy, M, Dobson, C
フォーマット: Journal article
言語:English
出版事項: BMJ Group 2014

類似資料